Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095738 | 1.00 | PPARG (0.46) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL1610643 | 0.99 | PPARG (0.45) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL2088199 | 0.91 | PTGER4 (0.44) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL3519333 | 0.91 | MRGPRX4 (0.52) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL3519330 | 0.91 | MRGPRX4 (0.52) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL2088195 | 0.91 | PTGER4 (0.44) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL2086121 | 0.90 | FFAR4 (0.43) | FFAR4PTPN1LMNAHPGDMRGPRX4 | |
| SCHEMBL2086119 | 0.90 | FFAR4 (0.43) | FFAR4PTPN1LMNAHPGDMRGPRX4 | |
| SCHEMBL2086541 | 0.88 | LMNA (0.49) | PPARGPPARAFFAR4GLRA1PTPN1 | |
| SCHEMBL13408005 | 0.84 | PPARG (0.42) | PPARGPPARAFFAR4KDM6BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288531-B2 | Preparation process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288531-B2 | Preparation process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110295000-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295000-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090111797-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009021943-A2 | NOVEL PREPARATION PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| US-7491717-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | disclosed |
| US-20080280887-A1 | Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| WO-2008022962-A2 | METHOD FOR PRODUCING N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC PROPERTIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | GPR119, HTR1D, TRPV1 | PPARG 634/4885PPARA 885/4885FFAR4 190/4885 |
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | CYP2F1, CYP11B2, CYP11B1 | PPARG 3768/4885PPARA 4550/4885FFAR4 4098/4885 |
| US-20080045705-A1 | Production Method | CYP2F1, CYP7A1, CYP1A1 | PPARG 2179/4885PPARA 3347/4885FFAR4 3455/4885 |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | PPARG 2294/4885PPARA 3147/4885FFAR4 1199/4885 |
| US-20110295000-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | PPARG 2179/4885PPARA 3347/4885FFAR4 3455/4885 |
| US-20090111797-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | PPARG 2294/4885PPARA 3147/4885FFAR4 1199/4885 |
| US-20080280887-A1 | Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions | CALCRL, CALCR, BDKRB2 | PPARG 2806/4885PPARA 3509/4885FFAR4 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.